AI-Enhanced Lung Preservation System: Machine Perfusion Tech

Publication ID: 24-11856944_0010_PTD

Published: October 26, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “AI-Enhanced Lung Preservation System: Machine Perfusion Tech,” Published Technical Disclosure No. 24-11856944_0010_PTD, Published October 26, 2025, available at https://archive.pr1or.art/24-11856944_0010_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,856,944.

Background and Problem Solved

Current organ preservation techniques are limited by hypothermic storage and lack of real-time monitoring, leading to suboptimal lung function and viability. The original patent addressed this by introducing a perfusion solution for machine perfusion of donor lungs at physiologic conditions. However, this approach has limitations in terms of adaptability, customization, and real-time feedback. The present invention overcomes these limitations by introducing a system that integrates machine perfusion with bio-artificial interfaces, AI-driven optimization, and personalized perfusion solutions.

Novelty and Inventive Step

The invention's novelty lies in the integration of machine perfusion with bio-artificial interfaces and AI-driven optimization, enabling real-time monitoring and adaptation to changing lung conditions. The inventive step is the use of AI-driven optimization to predict and prevent potential lung damage, and to tailor the perfusion solution and machine perfusion parameters to the specific lung's metabolic needs.

Alternative Embodiments and Variations

Alternative embodiments of the invention include the use of different bio-artificial interfaces, such as microfluidic channels or nanotechnology-based sensors. Variations of the invention could also include the integration of stem cells or other therapeutic agents to enhance lung viability and function.

Potential Commercial Applications and Market

The invention has significant commercial potential in the field of lung transplantation, with potential applications in organ preservation, transportation, and transplantation. The target market includes hospitals, research institutions, and biotechnology companies involved in lung transplantation and regenerative medicine.

CPC Classifications

Section	Class	Group
A	A01	A01N1/0226
A	A01	A01N1/0247

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biomedical engineering and organ preservation, specifically ex-vivo lung perfusion technologies with expertise in medical device design, biochemical solution formulation, and organ maintenance systems

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or medical researcher with advanced degrees in bioengineering, biochemistry, or medical technology, possessing knowledge of organ preservation techniques, machine perfusion systems, and advanced medical instrumentation

Obviousness Rationale

A PHOSITA would recognize that the PTD's AI-driven and bio-artificial interface approaches represent predictable technological extensions of the source patent's fundamental ex-vivo lung preservation method. The core innovation of real-time monitoring and adaptive perfusion parameters naturally follows from the source patent's detailed perfusion solution and machine perfusion methodology. The integration of machine learning and personalized metabolic profiling represents an incremental technological advancement that would be obvious to a skilled practitioner seeking to optimize organ preservation techniques.

Obvious Combinations & Variations

Source Patent Element

Perfusion liquid with specific nutrient, colloid, and chemical composition for lung preservation

PTD Variation

AI-driven customization of perfusion solution based on lung's genetic and proteomic profile

Obviousness Reasoning

Predictable application of known machine learning techniques to optimize existing perfusion solution formulation, representing a design choice for improving organ preservation outcomes

Source Patent Element

Ex-vivo machine perfusion of donor lungs at physiologic conditions

PTD Variation

Integration of bio-artificial interfaces and microfluidic channels for real-time lung function monitoring

Obviousness Reasoning

Known technique of enhancing medical monitoring systems using microfluidic and sensor technologies, providing predictable improvements in organ preservation methodology

Source Patent Element

Method of flushing donor lung with specific chemical composition

PTD Variation

Cloud-based platform for coordinating organ transport and real-time monitoring during preservation

Obviousness Reasoning

Obvious extension of existing medical tracking technologies to organ preservation, representing a standard technological improvement in medical logistics

Source Patent Element

Perfusion of lung with whole blood or red blood cells

PTD Variation

Integration of stem cells or therapeutic agents into preservation matrix

Obviousness Reasoning

Predictable application of regenerative medicine techniques to enhance organ preservation, representing a finite and foreseeable technological solution

35 U.S.C. § 103 Summary: Based on US Patent 11856944's comprehensive disclosure of ex-vivo lung perfusion methodology, the present publication demonstrates that the claimed variations in organ preservation technology would have been obvious to a person having ordinary skill in the art at the time of invention. The incremental technological advancements, including AI-driven optimization, bio-artificial interfaces, and personalized metabolic profiling, represent predictable extensions of the foundational preservation techniques disclosed in the source patent, thereby rendering subsequent claims obvious under 35 U.S.C. § 103.

Original Patent Information

Patent Number	US 11,856,944
Title	Organ care solution for ex-vivo machine perfusion of donor lungs
Assignee(s)	TRANSMEDICS, INC.